Yes. I see where you're coming from. Their starting dose is based on preclinicals - and it is higher than chemo drug starter but still very low. We need to know that dosage to know how it compares to the animal dosages. We know there was efficacy at lower doses for the animals, but we don't know if the lower doses were actually low doses. We can't quantify without knowing the fractional starting dose chosen for cohort one and knowing how it compared to lower doses in vivo preclinical. I wonder if they'll tell us in a pharmacokinetic pr. What do you think?